Immunic, Inc. (NASDAQ:IMUX) Receives Average Recommendation of "Buy" from Brokerages

Immunic, Inc. (NASDAQ:IMUX - Get Free Report) has been given a consensus rating of "Buy" by the seven analysts that are presently covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $11.80.

A number of brokerages have issued reports on IMUX. Leerink Partnrs raised Immunic to a "strong-buy" rating in a research report on Monday, September 9th. Leerink Partners reiterated an "outperform" rating and set a $5.00 target price on shares of Immunic in a report on Monday, September 9th. StockNews.com downgraded shares of Immunic from a "hold" rating to a "sell" rating in a research note on Monday, November 11th. EF Hutton Acquisition Co. I raised shares of Immunic to a "strong-buy" rating in a report on Monday, September 16th. Finally, B. Riley assumed coverage on Immunic in a research report on Tuesday, August 27th. They set a "buy" rating and a $6.00 target price on the stock.

Insider Buying and Selling

In other Immunic news, Director Richard Alan Rudick purchased 87,300 shares of the business's stock in a transaction that occurred on Tuesday, November 12th. The shares were purchased at an average price of $1.15 per share, for a total transaction of $100,395.00. Following the completion of the acquisition, the director now owns 87,300 shares of the company's stock, valued at approximately $100,395. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 3.00% of the company's stock.

Institutional Investors Weigh In On Immunic

Several institutional investors and hedge funds have recently modified their holdings of the stock. State Street Corp boosted its position in shares of Immunic by 7.5% in the third quarter. State Street Corp now owns 167,145 shares of the company's stock worth $276,000 after buying an additional 11,642 shares during the period. Virtu Financial LLC purchased a new stake in shares of Immunic in the third quarter worth about $50,000. Jane Street Group LLC boosted its position in shares of Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock worth $116,000 after buying an additional 38,553 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Immunic by 70.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company's stock worth $169,000 after buying an additional 42,383 shares during the period. Hedge funds and other institutional investors own 51.82% of the company's stock.

Immunic Price Performance

Immunic stock traded down $0.02 during midday trading on Wednesday, reaching $1.07. The company had a trading volume of 653,766 shares, compared to its average volume of 632,089. The company has a market capitalization of $96.38 million, a P/E ratio of -0.87 and a beta of 1.89. Immunic has a 12-month low of $0.97 and a 12-month high of $2.11. The firm's fifty day simple moving average is $1.26 and its 200-day simple moving average is $1.33.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.